middle.news
SomnoMed FY26 EBITDA Climbs 19% Amid CEO Shift and New Device Launch
8:31am on Friday 28th of August, 2026 AEST
•
Healthcare
Read Story
SomnoMed FY26 EBITDA Climbs 19% Amid CEO Shift and New Device Launch
8:31am on Friday 28th of August, 2026 AEST
Key Points
3% revenue growth to $114.5 million
EBITDA up 19% to $10.9 million with margin expansion
CEO Karen Borg assumes full leadership after co-CEO resignation
Virtus device launched for obstructive sleep apnea with bruxism
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Somnomed (ASX:SOM)
OPEN ARTICLE